Oncology ASCO 2023 – Gregory Lubiniecki With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.
Oncology ASCO 2023 – Arun Krishna With a 51% reduction in deaths, AstraZeneca’s ADAURA trial was one of the breakout stories of this year’s ASCO.
Oncology JP Morgan 2023 – Adi Hoess pharmaphorum editor-in-chief Jonah Comstock joins Adi Hoess, CEO of Affimed, at the Zeppelin Hotel in San Francisco, to learn about
Oncology Health Innovators – Dr. Jack Hoppin and Dr. John Babich A few weeks ago, pharmaphorum Editor-in-Chief Jonah Comstock popped in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich at their WeWork coworking
Views & Analysis Helsinn’s Riccardo Braglia on the patient perspective in can... Swiss cancer care company Helsinn has become unique in the industry by remaining a family business over three generations.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
